List view / Grid view

Boehringer Ingelheim

news

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

10 September 2013 | By Boehringer Ingelheim

Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial...

news

Phase III results: Once daily olodaterol* Respimat® provides effective and sustained improvements in lung function in patients with COPD1-3

9 September 2013 | By Boehringer Ingelheim

Data from two 48 week Phase III studies involving more than 3,000 patients...

news

New Phase III data presented for first time demonstrate tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS treatment

9 September 2013 | By

In patients with symptomatic asthma despite moderate-dose maintenance ICS therapy, the addition of tiotropium Respimat® significantly improves lung function and provides sustained bronchodilation over 24 hours.1

news

Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world’s leading maintenance therapy for chronic obstructive pulmonary disease (COPD)

9 September 2013 | By Boehringer Ingelheim

TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted...

news

Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases

3 September 2013 | By Boehringer Ingelheim

Boehringer Ingelheim announces new plans to expand body of evidence for Pradaxa®...

news

Boehringer Ingelheim to present highly anticipated data from landmark TIOSPIR™ trial at ERS 2013

2 September 2013 | By Boehringer Ingelheim

Results from TIOSPIR™ will be presented for the first time at the Annual Congress of the European Respiratory Society...

news

ESC Congress 2013: New data provide evidence for the positive safety and efficacy profile of Pradaxa® in various atrial fibrillation patient populations

26 August 2013 | By Boehringer Ingelheim

Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...

news

Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet

15 August 2013 | By OgilvyHealthPR London

Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the…

news

Boehringer Ingelheim announces full patient enrolment for two of its pivotal Phase III interferon-free hepatitis C clinical trials

15 August 2013 | By Boehringer Ingelheim

Boehringer Ingelheim announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete...

news

First half year 2013: Boehringer Ingelheim remains on growth path

14 August 2013 | By Boehringer Ingelheim

Boehringer Ingelheim grew further in the first half of 2013, despite difficult overall conditions...

news

Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

1 August 2013 | By Boehringer Ingelheim

Data from the LUX-Lung clinical trial programme...

news

First patient enrolled in new cardiovascular and renal outcomes trial for linagliptin in Type 2 Diabetes

31 July 2013 | By Boehringer Ingelheim

Boehringer Ingelheim (BI) and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta®). The CARMELINA1 (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with Type 2 Diabetes mellitus at high vascular risk) trial will investigate the…

news

Afatinib receives positive CHMP opinion for patients with EGFR mutation positive lung cancer in European Union

26 July 2013 | By Boehringer Ingelheim

"Boehringer Ingelheim welcomes the decision by the CHMP..."

news

Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding

17 July 2013 | By Boehringer Ingelheim

BI and EFSD commit €2.5 million to help accelerate European initiatives...

Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

news

FDA approves Gilotrif™ (afatinib) as first-line treatment for lung cancer patients with EGFR mutations

16 July 2013 | By Boehringer Ingelheim

First approval for afatinib, the frontrunner from Boehringer Ingelheim’s new oncology pipeline...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Boehringer Ingelheim